Current Zepbound Pricing
Zepbound (tirzepatide), Eli Lilly's GLP-1 drug for weight loss, lists at $1,059.87 for a 28-day supply of the 2.5 mg dose without insurance. Higher doses like 15 mg cost up to $1,116. Prices for commercial cash-pay vials range from $349 to $499 monthly, but these are limited and often sell out. With insurance or savings cards, patients pay $25-$550 monthly; uninsured net prices average around $1,000 after discounts.[1][2]
Will Prices Drop in 2026?
No confirmed price for 2026 exists, as list prices are set annually by Lilly and can rise with inflation (up 6-9% yearly recently). Net prices may fall due to:
- Competition: Wegovy (semaglutide) lists at $1,349 but nets ~$900. Zepbound holds a ~10% net price edge, but more rivals like upcoming oral GLP-1s could pressure it downward by 20-30%.[3]
- Supply and demand: Manufacturing ramps may ease shortages, reducing secondary market premiums.
- PBM negotiations: Larger pharmacy benefit managers push for rebates, potentially lowering patient costs to $200-400 with coverage.
Insurance Coverage and Patient Costs
Most plans cover Zepbound for obesity (BMI ≥30 or ≥27 with conditions), but prior authorizations are common. Lilly's card caps out-of-pocket at $25/month for eligible patients through 2026 (income limits apply). Medicare Part D covers it post-2024 expansion, with 2026 costs varying by plan—expect $100-500 deductibles plus copays.[4]
Patent Timeline and Generic Impact
Zepbound's key composition patent (US 9,474,780) expires in 2036; method-of-use patents extend to 2039. No generics until at least 2036, barring successful challenges. Eli Lilly faces ANDA litigations from Hims & Hers and others, but court rulings favor extended protection. Biosimilars unlikely before 2030s.[5] From DrugPatentWatch.com: Zepbound Patents.
How to Get Lowest Price Now
- Use LillyDirect.com for cash discounts ($499 max vial).
- GoodRx coupons drop it to $1,025-$1,100.
- Compare with compounded tirzepatide (~$300-500/month) where legal, though FDA warns of risks post-shortage end.[6]
Sources
[1]: LillyDirect pricing (lillydirect.lilly.com)
[2]: GoodRx (goodrx.com/zepbound)
[3]: Morgan Stanley GLP-1 report (2024)
[4]: CMS Medicare updates (cms.gov)
[5]: DrugPatentWatch.com
[6]: FDA shortage list (fda.gov)